Costco Wholesale Corporation vs Mesoblast Limited — how do they compare? Costco Wholesale Corporation trades at $945.95 (market cap $420.05B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Costco Wholesale Corporation is far larger — about 240× Mesoblast Limited's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 132 Days and Mesoblast Limited for 14 Days on average.
| COST | MESO | |
|---|---|---|
Market Cap | $420.05B | $1.75B |
Volume | 2,087,565 | 239,027 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $20.96 |
52-Week Low | $849.63 | $13.19 |
Typical Hold Time | 132 Days | 14 Days |
Enterprise Value | $407.33B | $1.83B |
Dividend Yield | 0.62% | — |
Signals from Pluang's Aura AI — not financial advice
Costco Wholesale Corporation (COST) trades at $942.25, up 0.7% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong March 2026 sales growth of 11.3% year-over-year, and fiscal 2025 revenue reached $275.24 billion with net income of $8.10 billion. Analyst consensus is strongly bullish with a $1,090 price target, though valuation ratios like P/E of 45.39 are elevated.
The outlook remains positive due to membership fee growth and expansion, but risks include high valuation sensitivity and competitive pressures. Earnings momentum is solid with recent beats, supporting the buy-rated sentiment, yet any market pullback could present a better entry point for long-term investors.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →